Innovative First-in-Human Study on Advanced Prostate Cancer Treatment Presented at AUA Meeting
Dr. Manish R. Patel, MD, who serves as the Director of Drug Development at the Florida Cancer Specialists & Research Institute, recently presented groundbreaking findings at the American Urological Association (AUA) meeting. He discussed the abstract titled "A Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for Heavily Pretreated Patients with Metastatic Castration-resistant Prostate Cancer Results from Additional Exploratory Analyses." This presentation highlighted the results from the first-in-human study focused on BMS-986365, a pioneering orally administered drug designed to degrade and inhibit the Androgen Receptor in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
The study revealed valuable data gathered from a multicenter investigation involving 68 patients, where subjects had been treated with various doses of BMS-986365, categorized into groups receiving 400mg, 600mg, or 900mg twice daily. Dr. Patel and his team reported that the treatment was well tolerated and exhibited a manageable safety profile, alongside promising anti-tumor effects. These insights suggest that BMS-986365 has the potential to address the challenge of resistance to existing Androgen Receptor Pathway Inhibitors (ARPI), making it a significant contender in the treatment landscape for mCRPC, regardless of the patients’ AR genomic status.
Dr. Patel expressed optimism about these findings, stating, ‘The results point towards a hopeful future in our pursuit to enhance survival rates among patients battling advanced prostate cancer.’
Florida Cancer Specialists (FCS) stands at the forefront of clinical oncology research, actively providing access to more than 150 clinical trials through their network of 29 clinics and three early-phase Drug Development Units (DDUs) located in Sarasota and Central Florida. Many of the pioneering cancer drugs available today in the United States underwent trial phases at FCS prior to receiving FDA approval, establishing the organization as a pivotal player in the evolution of cancer therapies.
In fact, the majority of recently approved cancer medications were initially made accessible to patients through FCS's clinical trial participation, showcasing the institute’s dedication to discovering and implementing effective treatment options. Under Dr. Patel’s leadership, FCS remains committed to improving patient outcomes through innovative and patient-centric approaches.
Dr. Lucio N. Gordan, the president and managing physician at FCS, emphasized their mission to provide personalized treatment solutions tailored to the unique genetic and health profiles of each patient. He remarked, ‘Through our comprehensive and expanding clinical trials program, we are contributing to global efforts aimed at saving lives by delivering truly personalized treatment options.’
The ongoing pursuit of clinical benefits linked to BMS-986365 adds a vital dimension to the treatment potential for advanced prostate cancer. Current analyses are underway, further underlining the importance of continued research and development in this vital field of oncology.
In light of these developments, it is crucial to stay informed about new advancements in cancer treatment. FCS continues to play a critical role in this journey, offering valuable insights and leading the charge in research that promises to change the landscape of prostate cancer therapy as we know it. For further details on this newly presented abstract and to access the study, individuals can refer to the Journal of Oncology for complete insights.
The study revealed valuable data gathered from a multicenter investigation involving 68 patients, where subjects had been treated with various doses of BMS-986365, categorized into groups receiving 400mg, 600mg, or 900mg twice daily. Dr. Patel and his team reported that the treatment was well tolerated and exhibited a manageable safety profile, alongside promising anti-tumor effects. These insights suggest that BMS-986365 has the potential to address the challenge of resistance to existing Androgen Receptor Pathway Inhibitors (ARPI), making it a significant contender in the treatment landscape for mCRPC, regardless of the patients’ AR genomic status.
Dr. Patel expressed optimism about these findings, stating, ‘The results point towards a hopeful future in our pursuit to enhance survival rates among patients battling advanced prostate cancer.’
Florida Cancer Specialists (FCS) stands at the forefront of clinical oncology research, actively providing access to more than 150 clinical trials through their network of 29 clinics and three early-phase Drug Development Units (DDUs) located in Sarasota and Central Florida. Many of the pioneering cancer drugs available today in the United States underwent trial phases at FCS prior to receiving FDA approval, establishing the organization as a pivotal player in the evolution of cancer therapies.
In fact, the majority of recently approved cancer medications were initially made accessible to patients through FCS's clinical trial participation, showcasing the institute’s dedication to discovering and implementing effective treatment options. Under Dr. Patel’s leadership, FCS remains committed to improving patient outcomes through innovative and patient-centric approaches.
Dr. Lucio N. Gordan, the president and managing physician at FCS, emphasized their mission to provide personalized treatment solutions tailored to the unique genetic and health profiles of each patient. He remarked, ‘Through our comprehensive and expanding clinical trials program, we are contributing to global efforts aimed at saving lives by delivering truly personalized treatment options.’
The ongoing pursuit of clinical benefits linked to BMS-986365 adds a vital dimension to the treatment potential for advanced prostate cancer. Current analyses are underway, further underlining the importance of continued research and development in this vital field of oncology.
In light of these developments, it is crucial to stay informed about new advancements in cancer treatment. FCS continues to play a critical role in this journey, offering valuable insights and leading the charge in research that promises to change the landscape of prostate cancer therapy as we know it. For further details on this newly presented abstract and to access the study, individuals can refer to the Journal of Oncology for complete insights.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.